Answers are grounded in this paper and cite their sources.
Background: The Schüttler pharmacokinetic-pharmacodynamic (PKPD) model for remimazolam was derived from healthy male volunteers (20-38 years; 64-99 kg). This study examined how body weight and age modify the relationship between effect-site concentration (Ce) and bispectral index (BIS) in Korean surgical patients. Methods: This retrospective study analyzed Schüttler-predicted remimazolam Ce and observed BIS from 52 adult patients under remimazolam-remifentanil total intravenous anesthesia. A linear mixed-effects model examined demographic modifiers of the Ce-BIS relationship, including Ce × weight and Ce × age interaction terms. Patients were stratified by body weight (< 60 vs. ≥ 60 kg) and age (< 40 vs. ≥ 40 years), reflecting the Schüttler development cohort boundaries. Prediction accuracy was assessed using median performance error (MDPE), and compared with the Masui, Zhou, and Eleveld models. Results: Body weight significantly modified the Ce-BIS relationship (Ce × weight interaction, P = 0.029), with lower body weight and older age each independently associated with lower observed BIS than model-predicted values. In patients weighing < 60 kg and aged ≥ 40 years, the Schüttler model showed greater negative bias (MDPE: -20.4%) than the Masui and Zhou models (MDPE: -17.5% and -18.9%, respectively), whereas the Eleveld model exhibited a qualitatively distinct, age-driven bidirectional bias pattern. Conclusions: Body weight and age significantly modify the Ce-BIS relationship in remimazolam-based anesthesia, with negative bias observed across all four PKPD models in low-body-weight older patients. These findings warrant prospective validation in larger and more diverse cohorts and remimazolam PKPD model refinement that adequately incorporates body size and age.
No takes yet. Share an insight, caveat, or question.
Yoon et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: